<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322762</url>
  </required_header>
  <id_info>
    <org_study_id>D1690R00002</org_study_id>
    <nct_id>NCT02322762</nct_id>
  </id_info>
  <brief_title>DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings</brief_title>
  <acronym>DISCOVER</acronym>
  <official_title>DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DISCOVER is a Non Interventional Study study to describe the disease management patterns and
      clinical evolution over three years in type 2 diabetes mellitus patients initiating a second
      line anti-diabetic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DISCOVER is a NIS study to describe the disease management patterns and clinical evolution
      over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic
      treatment. This study is a multi-country, multicenter, observational, prospective,
      longitudinal cohort study. The patients will be recruitted from countries in Latin America,
      Europe and Asia pac. It is estimated that approximately 13350 patients will be enrolled in
      total with each patient followed up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2014</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">August 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-diabetic treatments prescribed by physicians in a real-world setting.</measure>
    <time_frame>Up to 3 Years</time_frame>
    <description>The drugs (or their combinations) prescribed by physicians to patients initiating a 2nd line anti-diabetic treatment in a real-world setting will be described at inclusion and during 3 years follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control in terms of achieving HbA1c target goals and reducing body weight and blood pressure.</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anti-diabetic treatments</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression (incidence of microvascular and macrovascular complications).</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemic events.</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, using Patient Reported Outcomes questionnaires.</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Healthcare resources.</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">14173</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>One single cohort.</arm_group_label>
    <description>One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy
        after first line anti-diabetic therapy. Participating investigators will belong to primary,
        secondary or tertiary care clinics or hospitals in proportions trying to resemble the
        reality of management of this type of patients in each country.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of subject informed consent

          2. Female or male aged 18 years and over

          3. Diagnosed with type 2 diabetes mellitus

          4. Initiating a second line anti-diabetic therapy, either as add-on, or switching from
             one monotherapy to another.

        Exclusion Criteria:

          1. Diagnosis of type 1 diabetes mellitus

          2. Patient is pregnant

          3. Patients initiating a dual therapy after having previously received two different
             lines of monotherapy before (e.g.: Metformin → SU (Sulphonylureas) → SU+Add-on)

          4. Current treatment with chemotherapy, oral or iv steroids

          5. Patient is on dialysis or has had a renal transplant

          6. The patient is taking insulin as first line treatment

          7. The patient is taking dual therapy or a fixed dose combination treatment as first line
             treatment.

          8. The patient is taking herbal remedies / natural medicines as first line treatment

          9. Participation in an interventional trial

         10. Presence of any condition/circumstance which in the opinion of the investigator could
             significantly limit the complete follow up of the patient for 3 years (e.g.
             lifethreatening co-morbidities, tourist, non-native speaker or does not understand the
             local language where interpreter services are not reliably available, psychiatric
             disturbances, dementia, alcohol or drug abuse).

         11. Not willing to sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus Medina, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linong Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bong Soo Cha, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Yonsei University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Bahrain</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Oman</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Anti-diabetic management patterns</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

